Filed pursuant to Rule 424(b)(3)
Registration Statement No. 333-262003
The Greenrose Holding Company Inc.
Up to 29,716,728 Shares of Common Stock
(including 17,910,000 shares of Common Stock issuable
upon exercise of Warrants)
Up to 660,000 Warrants Exercisable for Common Stock
This prospectus supplement
supplements the prospectus dated February 9, 2022 (as amended and supplemented from time to time, the “Prospectus”), which
forms a part of our registration statement on Form S-l (No. 333-262003) that was declared effective on February 9, 2022 (as amended with
the Post-Effective Amendment No. 1 that was filed on June 10, 2022). This prospectus supplement is being filed to update and supplement
the information in the Prospectus with the information contained in our Current Reports on Form 8-K, filed with the Securities and Exchange
Commission on July 5, 2022 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.
The Prospectus and this prospectus
supplement relate to the resale from time to time of (i) 17,910,000 shares of our common stock, $0.0001 par value per share (our
“common stock”), issuable upon exercise of warrants to purchase Common Stock; (ii) 5,000,000 shares of common stock held by
the former equity holders of Theraplant, LLC (“Theraplant”) in connection with the Theraplant Merger (defined below); (iii) 2,266,350
shares of our common stock held or that will be held by our sponsor, Greenrose Associates LLC (our “Sponsor”); (iv) 4,430,378
shares of our common stock issued to True Harvest, LLC in connection the True Harvest Acquisition (defined below); (v) 88,000 shares of
our common stock and 528,000 private warrants (the “private warrants”, which upon any sale will become public warrants) held
by Imperial Capital, LLC, the representative of the underwriters in our initial public offering (“Imperial”); and (vi) 22,000
shares of our common stock and 132,000 Private warrants held by I-Bankers Securities, Inc, an underwriter in our initial public offering
(“I-Bankers” and, together with Theraplant, our Sponsor and Imperial, the “Selling Stockholders”).
We are not selling any securities
under the Prospectus and this prospectus supplement and will not receive any of the proceeds from the sale of our common stock by the
Selling Stockholders, except with respect to amounts received by us upon exercise of the Warrants.
The Selling Stockholders may
sell the shares of common stock and private warrants, as applicable, included in the Prospectus and this prospectus supplement in a number
of different ways and at varying prices. We provide more information about how the Selling Stockholders may sell the shares in the section
of the Prospectus entitled “Plan of Distribution.” Each of the Selling Stockholders is an “underwriter” within
the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.
Our common stock and our public
warrants (our “Public Warrants) are traded on The Over The Counter “OTCQX” Market and OTCQB Market under the symbols
“GNRS” and “GNRS.W,” respectively. On July 5, 2022, the closing price of our common stock was $2.75 per share
and the closing price of our Public Warrants was $0.13 per warrant.
This prospectus supplement
updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in
combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus (as amended and supplemented from time to time) and if there is any inconsistency between the information in the Prospectus
and this prospectus supplement, you should rely on the information in this prospectus supplement.
We are an “emerging
growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.
Investing in our securities
involves a high degree of risk. See “Risk Factors” beginning on page 6 of the Prospectus for a discussion of information that
should be considered in connection with an investment in our securities.
Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus
and this prospectus supplement are truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is July
6, 2022
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 5, 2022 (June 28, 2022)
THE GREENROSE HOLDING COMPANY INC.
(Exact name of Registrant as specified in its charter)
Delaware |
|
001-39217 |
|
84-2845696 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
incorporation or organization) |
|
|
|
Identification Number) |
111 Broadway Amityville, NY |
|
11701 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (516) 346-5270
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation to the Registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the Registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class |
|
Name of Each Exchange on Which Registered |
Units, each consisting of one share of common stock and one redeemable warrant |
|
OTC Pink |
Common stock, par value $0.0001 per share |
|
OTCQX |
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share |
|
OTCQB |
Item 8.01 Other Events.
On June 28, 2022, The Greenrose Holding Company
Inc. (the “Company”) received a complaint filed by Shareholder Representative Services LLC (the “Plaintiff”) against
the Company in the Connecticut Superior Court. In the complaint, the Plaintiff generally alleges breach of contract, breach of the covenant
of good faith and fair dealing, and conversion with respect to the Agreement and Plan of Merger effective as of March 12, 2021 and its
Amendments 1 and 2 (collectively, the “Merger Agreement”) between the Plaintiff, as representative of the Selling Securityholders
of Theraplant (as defined in the Merger Agreement), and the Company. The Company intends to defend itself vigorously.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 5, 2022 |
The Greenrose Holding Company Inc. |
|
|
|
By: |
/s/ William F. Harley III |
|
Name: |
William F. Harley III |
|
Title: |
Chief Executive Officer |
2
Greenrose (CE) (USOTC:GNRS)
過去 株価チャート
から 5 2024 まで 6 2024
Greenrose (CE) (USOTC:GNRS)
過去 株価チャート
から 6 2023 まで 6 2024